Accelerated Caco-2 cell permeability model for drug discovery

J Pharmacol Toxicol Methods. 2013 Nov-Dec;68(3):334-9. doi: 10.1016/j.vascn.2013.07.004. Epub 2013 Aug 3.

Abstract

Introduction: By culturing Caco-2 cells according to a new and optimized protocol, it has been possible to accelerate the cell culture process in such a way that the cells can be used for experiments after only 6 days. The accelerated Caco-2 model has been compared to the traditional model (requiring 21-25 days of culture) in terms of tightness of the junctions, ability to rank chemical compounds for apparent permeability, active efflux and to discriminate P-gp substrates.

Methods and results: In the new protocol, Caco-2 cells were cultured with the classical Caco-2 medium supplemented with puromycin. The initial cell seeding density was increased two times compared to the traditional procedure and the presence of a low concentration of puromycin in the culture medium reduced the Caco-2 permeability of mannitol. Bi-directional studies were performed with known P-gp substrates (rhodamine 123, digoxin and saquinavir) and with a total of 20 marketed drugs covering a wide range of physicochemical characteristics and therapeutic indications. Strong correlations were obtained between the apparent permeability in absorptive (Papp A→B) or secretory (Papp B→A) of the drugs in the accelerated model and in the traditional models and comparable efflux ratios were observed in the two studied models.

Discussion: The new protocol reduces costs for screening and leads to higher throughput compared to traditional Caco-2 cell models. This accelerated model provides short time-feedback to the drug design during the early stage of drug discovery.

Keywords: Accelerated model; Caco-2 cells; Drug discovery; Drug permeability; Efflux ratio; P-glycoprotein; Puromycin.

Publication types

  • Comparative Study

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism*
  • Caco-2 Cells
  • Cell Membrane Permeability
  • Costs and Cost Analysis
  • Digoxin / pharmacology
  • Drug Design
  • Drug Discovery
  • High-Throughput Screening Assays / methods
  • Humans
  • Mannitol / pharmacokinetics*
  • Models, Biological*
  • Puromycin / chemistry
  • Rhodamine 123 / pharmacology
  • Saquinavir / pharmacology
  • Time Factors

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Rhodamine 123
  • Mannitol
  • Puromycin
  • Digoxin
  • Saquinavir